​

TransMedics Group (TMDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TMDX Stock Forecast

TransMedics Group stock forecast is as follows: an average price target of $116.33 (represents a 88.54% upside from TMDX’s last price of $61.70) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

TMDX Price Target

The average price target for TransMedics Group (TMDX) is $116.33 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $145.00 to $90.00. This represents a potential 88.54% upside from TMDX's last price of $61.70.

TMDX Analyst Ratings

Buy

According to 9 Wall Street analysts, TransMedics Group's rating consensus is 'Buy'. The analyst rating breakdown for TMDX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

TransMedics Group Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 11, 2024David RescottRobert W. Baird$120.00$67.3678.15%94.49%
Dec 11, 2024Matt O'BrienPiper Sandler$90.00$67.3633.61%45.87%
Oct 29, 2024Joe VruwinkRobert W. Baird$150.00$88.7069.11%143.11%
Oct 29, 2024Jason MillsCanaccord Genuity$109.00$126.24-13.66%76.66%
Oct 29, 2024Mike MatsonNeedham$109.00$126.24-13.66%76.66%
Oct 29, 2024Suraj KaliaOppenheimer$125.00$126.24-0.98%102.59%
Sep 23, 2024David RescottRobert W. Baird$200.00$159.5025.39%224.15%
Sep 04, 2024Matt O'BrienPiper Sandler$180.00$158.4213.62%191.73%
Aug 21, 2024Mike MatsonNeedham$208.00$166.1825.17%237.12%
Aug 01, 2024William PlovanicCanaccord Genuity$169.00$164.023.04%173.91%
Aug 01, 2024Suraj KaliaOppenheimer$200.00$142.2640.59%224.15%
Jul 15, 2024Patrick WoodMorgan Stanley$145.00$142.191.98%135.01%
Jul 15, 2024Matt O'BrienPiper Sandler$170.00$142.1919.56%175.53%
Jun 03, 2024George SellersStephens$151.00$133.6313.00%144.73%
Jan 06, 2023Morgan Stanley$63.00$57.0210.49%2.11%
Aug 03, 2022Morgan Stanley$37.00$38.63-4.22%-40.03%
Aug 02, 2022Oppenheimer$45.00$37.9918.45%-27.07%
Jul 26, 2022Cowen & Co.$45.00$35.1827.91%-27.07%
Jun 29, 2022Morgan Stanley$34.00$31.966.37%-44.89%
Jun 28, 2022Cowen & Co.$39.00$33.7815.45%-36.79%
May 04, 2022Morgan Stanley$25.00$30.62-18.35%-59.48%

The latest TransMedics Group stock forecast, released on Dec 11, 2024 by David Rescott from Robert W. Baird, set a price target of $120.00, which represents a 78.15% increase from the stock price at the time of the forecast ($67.36), and a 94.49% increase from TMDX last price ($61.70).

TransMedics Group Price Target by Period

1M3M12M
# Anlaysts2714
Avg Price Target$105.00$129.00$151.86
Last Closing Price$61.70$61.70$61.70
Upside/Downside70.18%109.08%146.13%

In the current month, the average price target of TransMedics Group stock is $105.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 70.18% increase as opposed to TransMedics Group's last price of $61.70. This month's average price target is down -18.60% compared to last quarter, and down -30.86% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024Piper SandlerOverweightOverweightHold
Oct 29, 2024William BlairOutperformOutperformHold
Oct 29, 2024StephensBuyBuyHold
Oct 29, 2024Canaccord GenuityBuyBuyHold
Oct 29, 2024NeedhamBuyBuyHold
Oct 29, 2024OppenheimerOutperformOutperformHold
Oct 24, 2024Piper SandlerOverweightOverweightHold
Sep 24, 2024StephensBuyBuyHold
Sep 05, 2024Cowen & Co.BuyBuyHold
Sep 04, 2024Piper SandlerOverweightOverweightHold
Aug 26, 2024Canaccord GenuityBuyBuyHold
Aug 21, 2024StephensBuyBuyHold
Aug 21, 2024NeedhamBuyInitialise
Aug 01, 2024OppenheimerOutperformOutperformHold
Jul 15, 2024StephensBuyBuyHold
Jul 15, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jul 15, 2024Piper SandlerOverweightOverweightHold
Jun 21, 2024StephensBuyBuyHold
Jun 07, 2024Cowen & Co.BuyBuyHold
Jun 03, 2024StephensOverweightInitialise
May 01, 2024OppenheimerOutperformOutperformHold
May 01, 2024Cowen & Co.BuyBuyHold
Mar 28, 2024Piper SandlerOverweightInitialise
Feb 27, 2024OppenheimerOutperformOutperformHold
Jul 19, 2023William BlairOutperformInitialise
Jan 06, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Dec 16, 2022Cowen & Co.OutperformOutperformHold
Aug 03, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Aug 02, 2022OppenheimerOutperformOutperformHold
Jul 26, 2022Cowen & Co.OutperformOutperformHold
Jun 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jun 28, 2022Cowen & Co.OutperformOutperformHold
Apr 26, 2022Zacks Investment ResearchHoldUpgrade
Feb 25, 2022Morgan StanleyEqual-WeightEqual-WeightHold

TransMedics Group's last stock rating was published by Piper Sandler on Dec 11, 2024. The company gave TMDX a "Overweight" rating, the same as its previous rate.

TransMedics Group Financial Forecast

TransMedics Group Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$66.43M$52.47M$41.55M$31.38M$25.68M$20.52M$15.88M$9.67M$5.37M$8.17M$7.05M$7.63M$7.09M$3.39M$7.53M$6.06M$7.21M
Avg Forecast$173.16M$162.77M$152.81M$138.36M$142.91M$134.34M$128.72M$118.68M$109.65M$115.00M$98.84M$83.78M$68.49M$49.19M$42.42M$37.93M$24.45M$18.88M$16.27M$9.66M$7.51M$6.34M$7.42M$7.10M$6.06M$5.55M$2.75M$7.14M$6.97M$6.67M
High Forecast$177.88M$167.21M$156.98M$142.13M$146.80M$138.00M$132.24M$121.49M$111.22M$115.43M$98.84M$86.07M$69.81M$49.19M$43.58M$38.97M$25.11M$18.88M$16.27M$9.66M$7.51M$6.34M$7.42M$7.10M$6.06M$5.55M$2.75M$7.14M$6.97M$6.67M
Low Forecast$168.60M$158.48M$148.78M$134.71M$139.14M$130.80M$125.33M$115.73M$108.26M$114.57M$98.84M$81.57M$67.75M$49.19M$41.30M$36.94M$23.80M$18.88M$16.27M$9.66M$7.51M$6.34M$7.42M$7.10M$6.06M$5.55M$2.75M$7.14M$6.97M$6.67M
# Analysts444433356322422211112222222211
Surprise %-------------1.35%1.24%1.10%1.28%1.36%1.26%1.64%1.29%0.85%1.10%0.99%1.26%1.28%1.23%1.05%0.87%1.08%

TransMedics Group's average Quarter revenue forecast for Dec 23 based on 4 analysts is $68.49M, with a low forecast of $67.75M, and a high forecast of $69.81M. TMDX's average Quarter revenue forecast represents a 3.11% increase compared to the company's last Quarter revenue of $66.43M (Sep 23).

TransMedics Group EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433356322422211112222222211
EBITDA-------------$-28.34M$1.52M$-1.53M$-5.69M$-5.73M$-10.53M$-9.09M$-11.21M$-11.52M$-9.25M$-6.52M$-4.90M$-3.71M$-7.12M$-7.43M$-7.75M$-6.85M
Avg Forecast$-112.36M$-105.62M$-99.16M$-89.78M$-92.73M$-87.17M$-83.53M$-77.01M$-71.15M$-74.62M$-64.14M$-8.67M$-44.44M$-31.92M$-27.53M$-7.88M$-11.15M$-12.36M$-10.66M$-7.17M$-4.92M$-4.16M$-4.86M$-6.52M$-3.97M$-3.64M$-1.80M$-7.06M$-4.56M$-4.37M
High Forecast$-109.40M$-102.83M$-96.54M$-87.41M$-90.29M$-84.87M$-81.33M$-75.10M$-70.25M$-74.34M$-64.14M$-6.94M$-43.96M$-31.92M$-26.80M$-6.31M$-8.92M$-12.36M$-10.66M$-5.73M$-4.92M$-4.16M$-4.86M$-5.21M$-3.97M$-3.64M$-1.80M$-5.65M$-4.56M$-4.37M
Low Forecast$-115.43M$-108.50M$-101.86M$-92.23M$-95.26M$-89.55M$-85.81M$-78.83M$-72.17M$-74.90M$-64.14M$-10.41M$-45.30M$-31.92M$-28.28M$-9.46M$-13.38M$-12.36M$-10.66M$-8.60M$-4.92M$-4.16M$-4.86M$-7.82M$-3.97M$-3.64M$-1.80M$-8.47M$-4.56M$-4.37M
Surprise %-------------0.89%-0.06%0.19%0.51%0.46%0.99%1.27%2.28%2.77%1.90%1.00%1.23%1.02%3.95%1.05%1.70%1.57%

2 analysts predict TMDX's average Quarter EBITDA for Sep 23 to be $-31.92M, with a high of $-31.92M and a low of $-31.92M. This is -2192.96% lower than TransMedics Group's previous annual EBITDA (Jun 23) of $1.52M.

TransMedics Group Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433356322422211112222222211
Net Income-------------$-25.42M$-1.00M$-2.64M$-6.72M$-7.43M$-11.52M$-10.56M$-12.67M$-12.96M$-10.67M$-7.92M$-6.31M$-5.09M$-8.50M$-8.85M$-9.18M$-8.28M
Avg Forecast$22.57M$19.68M$20.30M$17.20M$15.33M$13.36M$13.76M$9.95M$5.72M$10.47M$7.52M$-10.54M$-2.47M$-5.79M$-4.67M$-9.58M$-12.61M$-14.54M$-12.28M$-8.71M$-15.19M$-12.54M$-9.96M$-7.92M$-8.78M$-11.30M$-14.88M$-8.41M$-13.76M$-15.79M
High Forecast$23.37M$20.37M$21.02M$17.81M$15.87M$13.83M$14.24M$11.27M$7.94M$10.48M$7.53M$-8.43M$-1.48M$-5.59M$-4.51M$-7.66M$-10.09M$-14.54M$-12.28M$-6.97M$-15.19M$-12.54M$-9.96M$-6.33M$-8.78M$-11.30M$-14.88M$-6.73M$-13.76M$-15.79M
Low Forecast$21.80M$19.00M$19.60M$16.61M$14.81M$12.90M$13.28M$8.29M$3.81M$10.46M$7.52M$-12.65M$-4.69M$-5.99M$-4.83M$-11.50M$-15.13M$-14.54M$-12.28M$-10.45M$-15.19M$-12.54M$-9.96M$-9.50M$-8.78M$-11.30M$-14.88M$-10.09M$-13.76M$-15.79M
Surprise %-------------4.39%0.21%0.28%0.53%0.51%0.94%1.21%0.83%1.03%1.07%1.00%0.72%0.45%0.57%1.05%0.67%0.52%

TransMedics Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TMDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

TransMedics Group SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433356322422211112222222211
SG&A-------------$30.65M$29.36M$24.98M$21.73M$16.85M$17.38M$13.94M$12.00M$10.34M$9.16M$6.97M$6.18M$5.49M$5.87M$6.65M$6.17M$6.52M
Avg Forecast$154.14M$144.89M$136.02M$123.16M$127.21M$119.58M$114.59M$105.64M$97.60M$102.37M$87.99M$9.28M$60.97M$43.79M$37.76M$8.44M$11.94M$16.77M$14.46M$7.67M$6.67M$5.64M$6.59M$6.97M$5.39M$4.93M$2.44M$6.32M$6.19M$5.93M
High Forecast$158.35M$148.84M$139.73M$126.52M$130.68M$122.84M$117.71M$108.14M$99.01M$102.75M$87.99M$11.14M$62.14M$43.79M$38.79M$10.13M$14.33M$16.77M$14.46M$9.21M$6.67M$5.64M$6.59M$8.37M$5.39M$4.93M$2.44M$7.58M$6.19M$5.93M
Low Forecast$150.08M$141.07M$132.44M$119.92M$123.86M$116.43M$111.57M$103.02M$96.37M$101.98M$87.99M$7.43M$60.31M$43.79M$36.77M$6.75M$9.55M$16.77M$14.46M$6.14M$6.67M$5.64M$6.59M$5.58M$5.39M$4.93M$2.44M$5.06M$6.19M$5.93M
Surprise %-------------0.70%0.78%2.96%1.82%1.00%1.20%1.82%1.80%1.83%1.39%1.00%1.15%1.11%2.40%1.05%1.00%1.10%

TransMedics Group's average Quarter SG&A projection for Dec 23 is $60.97M, based on 4 Wall Street analysts, with a range of $60.31M to $62.14M. The forecast indicates a 98.90% rise compared to TMDX last annual SG&A of $30.65M (Sep 23).

TransMedics Group EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts444433356322422211112222222211
EPS-------------$-0.78$-0.03$-0.08$-0.21$-0.25$-0.41$-0.38$-0.46$-0.47$-0.39$-0.29$-0.23$-0.19$-0.36$-0.42$-0.43$-0.39
Avg Forecast$0.63$0.55$0.57$0.48$0.43$0.37$0.39$0.28$0.16$0.29$0.21$-0.02$-0.07$-0.16$-0.13$-0.25$-0.30$-0.41$-0.35$-0.38$-0.43$-0.36$-0.28$-0.29$-0.25$-0.32$-0.42$-0.40$-0.39$-0.45
High Forecast$0.65$0.57$0.59$0.50$0.44$0.39$0.40$0.32$0.22$0.29$0.21$-0.02$-0.04$-0.16$-0.13$-0.24$-0.29$-0.41$-0.35$-0.38$-0.43$-0.36$-0.28$-0.29$-0.25$-0.32$-0.42$-0.40$-0.39$-0.45
Low Forecast$0.61$0.53$0.55$0.47$0.41$0.36$0.37$0.23$0.11$0.29$0.21$-0.02$-0.13$-0.17$-0.14$-0.25$-0.31$-0.41$-0.35$-0.38$-0.43$-0.36$-0.28$-0.29$-0.25$-0.32$-0.42$-0.40$-0.39$-0.45
Surprise %-------------4.81%0.24%0.33%0.70%0.61%1.18%1.00%1.07%1.32%1.38%1.00%0.92%0.59%0.85%1.06%1.10%0.87%

According to undefined Wall Street analysts, TransMedics Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TMDX previous annual EPS of $NaN (undefined).

TransMedics Group Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TELATELA Bio$2.76$8.00189.86%Buy
LUNGPulmonx$6.13$13.00112.07%Buy
DCTHDelcath Systems$11.94$22.0084.25%Buy
TMDXTransMedics Group$65.71$116.3377.04%Buy
OFIXOrthofix Medical$17.93$24.0033.85%
NPCENeuroPace$11.52$15.0030.21%Buy
INMDInMode$17.83$21.7521.99%Hold
INSPInspire Medical Systems$190.71$223.1717.02%Buy
NARIInari Medical$56.16$64.0013.96%Buy
CVRXCVRx$13.16$14.258.28%Buy
PODDInsulet$263.35$268.001.77%Buy
MASIMasimo$174.07$168.33-3.30%Buy
PENPenumbra$247.55$230.25-6.99%Buy

TMDX Forecast FAQ

Is TransMedics Group a good buy?

Yes, according to 9 Wall Street analysts, TransMedics Group (TMDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 77.78% of TMDX's total ratings.

What is TMDX's price target?

TransMedics Group (TMDX) average price target is $116.33 with a range of $90 to $145, implying a 88.54% from its last price of $61.7. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will TransMedics Group stock go up soon?

According to Wall Street analysts' prediction for TMDX stock, the company can go up by 88.54% (from the last price of $61.7 to the average price target of $116.33), up by 135.01% based on the highest stock price target, and up by 45.87% based on the lowest stock price target.

Can TransMedics Group stock reach $90?

TMDX's average twelve months analyst stock price target of $116.33 supports the claim that TransMedics Group can reach $90 in the near future.

What is TransMedics Group's current price target trend?

2 Wall Street analysts forecast a $105 price target for TransMedics Group (TMDX) this month, up 70.18% from its last price of $61.7. Compared to the last 3 and 12 months, the average price target increased by 109.08% and increased by 146.13%, respectively.

What are TransMedics Group's analysts' financial forecasts?

TransMedics Group's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $524.65M (high $538.53M, low $511M), average EBITDA is $-340M (high $-332M, low $-349M), average net income is $52.39M (high $55.22M, low $49.28M), average SG&A $467.02M (high $479.38M, low $454.87M), and average EPS is $1.47 (high $1.55, low $1.38). TMDX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $627.1M (high $644.2M, low $610.57M), average EBITDA is $-407M (high $-396M, low $-418M), average net income is $79.75M (high $82.57M, low $77.01M), average SG&A $558.22M (high $573.44M, low $543.51M), and average EPS is $2.23 (high $2.31, low $2.16).

Did the TMDX's actual financial results beat the analysts' financial forecasts?

Based on TransMedics Group's last annual report (Dec 2023), the company's revenue was $241.62M, beating the average analysts forecast of $198.04M by 22.01%. Apple's EBITDA was $-28.727M, missing the average prediction of $-112M by -74.30%. The company's net income was $-25.028M, beating the average estimation of $-22.504M by 11.21%. Apple's SG&A was $119.55M, missing the average forecast of $150.96M by -20.80%. Lastly, the company's EPS was $-0.0008, missing the average prediction of $-0.608 by -99.87%. In terms of the last quarterly report (Sep 2023), TransMedics Group's revenue was $66.43M, beating the average analysts' forecast of $49.19M by 35.05%. The company's EBITDA was $-28.335M, missing the average prediction of $-31.918M by -11.22%. TransMedics Group's net income was $-25.422M, beating the average estimation of $-5.787M by 339.31%. The company's SG&A was $30.65M, missing the average forecast of $43.79M by -29.99%. Lastly, the company's EPS was $-0.78, beating the average prediction of $-0.162 by 380.98%